Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 13/20 | 0.42 |
| ▸ | FNTB | P49356 | 13/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HRAS | P01112 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7748858 | 0.87 | FNTA (0.41) | FNTAFNTBHRH3OPRM1OPRK1 | |
| SCHEMBL7743228 | 0.85 | FNTA (0.43) | FNTAFNTBHRH3GPR119HRAS | |
| SCHEMBL7747674 | 0.85 | FNTA (0.45) | FNTAFNTBHRH3OPRM1OPRK1 | |
| SCHEMBL7747657 | 0.83 | FNTA (0.42) | FNTAFNTBHRH3GPR119CYP2D6 | |
| SCHEMBL7743244 | 0.82 | GPR119 (0.49) | FNTAFNTBHRH3GPR119 | |
| SCHEMBL7743208 | 0.81 | FNTA (0.47) | FNTAFNTBHRH3GPR119HRAS | |
| SCHEMBL7162634 | 0.80 | FNTA (0.52) | FNTAFNTBHRASKRASPGGT1B | |
| SCHEMBL7747665 | 0.79 | FNTA (0.43) | FNTAFNTBHRH3CYP2D6HRAS | |
| SCHEMBL7124953 | 0.76 | HRH3 (0.38) | HRH3GPR119 | |
| SCHEMBL7747638 | 0.73 | CYP2D6 (0.41) | FNTAFNTBHRH3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001022963-A1 | METHOD OF PREVENTING OSTEOPOROSIS | MERCK & CO., INC. (US) | 2001-04-05 | — | — | WO | disclosed |